Wide Ranks

BMY

Bristol-Myers Squibb Company

59.27

Top Statistics
Market Cap 120 B Forward PE 8.40 Revenue Growth 8.40 %
Current Ratio 1.24 Trailing PE 0.0000 Earnings Growth -35.80 %
Profit Margins -15.30 % Peg Ratio Dividend Yield 4.05 %
Enterprice / EBITA 8.54 Enterprise / Revenue 3.45 Price To Sales Trailing12 Months 2.53
Profitability
Profit Margins -15.30 % Operating Margins 18.48 %
Balance Sheet
Total Cash 8 B Total Cash Per Share 3.99 Total Debt 51 B
Total Debt To Equity 299.05 Current Ratio 1.24 Book Value Per Share 8.45
All Measures
Return On Equity -0.3133 Total Debt 51 B Beta 0.4410
Last Split Date 997 M Fifty Two Week Low 39.35 Audit Risk 9
Target Mean Price 59.64 Short Percent Of Float 0.0127 Trailing Peg Ratio 204.18 %
Last Fiscal Year End 1 B Average Volume10days 11 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0011 Ebitda Margins 40.40 % Trailing PE 0.0000
Most Recent Quarter 1 B Gmt Off Set Milliseconds -18000000 Fifty Day Average 54.21
Open 58.82 State NJ Return On Assets 0.0607
Time Zone Short Name EST Board Risk 5 Trailing Eps -3.58
Day Low 58.78 Shares Outstanding 2 B Compensation Risk 1
Price Hint 2 Website https://www.bms.com 52 Week Change 0.2003
Recommendation Key hold Quick Ratio 101.60 % Last Split Factor 1000000:951777
Is_sp_500 True Profit Margins -15.30 % Debt To Equity 299.05
Fifty Two Week High 61.08 Enterprise To Revenue 3.45 Operating Cashflow 15 B
Five Year Avg Dividend Yield 341.00 % Market Cap 120 B Quote Type EQUITY
Industry Drug Manufacturers - General Ex Dividend Date 1 B Overall Risk 3
Long Name Bristol-Myers Squibb Company Current Ratio 1.24 Number Of Analyst Opinions 22
Governance Epoch Date 1 B Forward PE 8.40 Regular Market Volume 3 M
Short Ratio 234.00 % Message Board Id finmb_25798 Shares Short Prior Month 22 M
City Princeton Uuid 124a4488-9ef3-3d5f-ba4c-95716202653d Previous Close 58.74
First Trade Date Epoch Utc 76 M Book Value 8.45 Volume 3 M
Price To Book 7.01 Total Cash Per Share 3.99 Total Revenue 47 B
Shares Short Previous Month Date 1 B Target Median Price 60.50 Max Age 86400
Recommendation Mean 2.74 Sand P52 Week Change 0.3133 Operating Margins 18.48 %
Last Dividend Value 0.6000 Net Income To Common -7257999872 Ask 59.28
Implied Shares Outstanding 2 B Average Daily Volume10 Day 11 M Total Cash 8 B
Revenue Per Share 23.41 Dividend Rate 2.40 Date Short Interest 1 B
Share Holder Rights Risk 2 Regular Market Previous Close 58.74 Target Low Price 39.00
Free Cashflow 17 B Dividend Yield 4.05 % Target High Price 73.00
Address1 Route 206 & Province Line Road Trailing Annual Dividend Rate 2.40 Average Volume 11 M
Earnings Quarterly Growth -37.20 % Forward Eps 7.03 Compensation As Of Epoch Date 1 B
Regular Market Day High 59.51 Day High 59.51 Shares Short 25 M
Regular Market Open 58.82 Industry Key drug-manufacturers-general Bid 59.23
Earnings Growth -35.80 % Revenue Growth 8.40 % Shares Percent Shares Out 0.0127
Currency USD Time Zone Full Name America/New_York Is_nasdaq_100 False
Zip 08543 Payout Ratio 59.84 % Regular Market Day Low 58.78
Held Percent Institutions 0.7842 Current Price 59.27 Enterprise To Ebitda 8.54
Financial Currency USD Trailing Annual Dividend Yield 4.09 % Gross Margins 75.87 %
Industry Disp Drug Manufacturers - General Country United States Float Shares 2 B
Two Hundred Day Average 48.68 Ir Website http://www.bms.com/investors/Pages/home.aspx Enterprise Value 163 B
Price To Sales Trailing12 Months 2.53 Last Dividend Date 1 B Ebitda 19 B
Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.

The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis.

In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer.

It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

The company was formerly known as Bristol-Myers Company.

Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.